Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.

Br J Cancer · 2016 · PMC4984865 · PMID 27022826

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

a nonsignificant trendP =0.06so close (0.05 < p ≤ 0.1)

There was a nonsignificant trend towards a lower incidence of peripheral sensory neuropathy (2.7% vs 9.0%, P =0.06).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.